Smoking status and immunotherapy outcomes in advanced esophageal squamous-cell carcinoma: a meta-analysis

Smoking is a major risk factor in esophageal squamous cell carcinoma (ESCC) and may influence response to immune checkpoint inhibitors (ICIs). We aimed to evaluate the association between smoking status and overall survival (OS) in patients with advanced ESCC treated with ICIs. PubMed, Web of Science, Scopus, and Cochrane Library were searched through March 10, 2026 for randomized trials reporting OS according to smoking status in advanced ESCC treated with ICIs. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Nine reports from eight trials involving 4,076 patients were included. In the overall population, ICIs significantly improved OS compared with control treatment (HR 0.69, 95% CI 0.65–0.74; p < 0.001). In smoking-stratified analyses of the overall population, significant OS benefits were observed in never smokers (HR 0.75, 95% CI 0.66–0.85; p = 0.001), and former smokers (HR 0.75, 95% CI 0.60–0.92; p = 0.020), whereas OS among current smokers did not reach statistical significance (HR 0.60, 95% CI 0.30–1.18; p = 0.095). However, Treatment-by-smoking interaction analyses did not detect statistically significant evidence. When participants were categorized as never smokers versus ever smokers (former or current smokers), ICIs were associated with significantly improved OS in both groups: never smokers (HR 0.75, 95% CI 0.66–0.85; p = 0.001) and ever smokers (HR 0.69, 95% CI 0.61–0.78; p = 0.003). ICIs were associated with improved OS in advanced ESCC in the overall population. However, in analyses by smoking status, OS benefit did not reach statistical significance among current smokers. Treatment-by-smoking interaction analyses did not detect statistically significant evidence. The analyses were limited by the small subgroup sizes, and further studies with larger smoking-stratified populations are needed.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-16
DOI
https://doi.org/10.1186/s12885-026-17262-x
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Smoking status and immunotherapy outcomes in advanced esophageal squamous-cell carcinoma: a meta-analysis

Muhammed Elhadi, Mohammed S. Beshr, Markus Moehler
2 links
BMC Cancer
Esophageal Cancer Research and Treatment
article

Smoking status and immunotherapy outcomes in advanced esophageal squamous-cell carcinoma: a meta-analysis

Muhammed Elhadi, Mohammed S. Beshr, Markus Moehler
article en

Abstract

Smoking is a major risk factor in esophageal squamous cell carcinoma (ESCC) and may influence response to immune checkpoint inhibitors (ICIs). We aimed to evaluate the association between smoking status and overall survival (OS) in patients with advanced ESCC treated with ICIs. PubMed, Web of Science, Scopus, and Cochrane Library were searched through March 10, 2026 for randomized trials reporting OS according to smoking status in advanced ESCC treated with ICIs. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Nine reports from eight trials involving 4,076 patients were included. In the overall population, ICIs significantly improved OS compared with control treatment (HR 0.69, 95% CI 0.65–0.74; p < 0.001). In smoking-stratified analyses of the overall population, significant OS benefits were observed in never smokers (HR 0.75, 95% CI 0.66–0.85; p = 0.001), and former smokers (HR 0.75, 95% CI 0.60–0.92; p = 0.020), whereas OS among current smokers did not reach statistical significance (HR 0.60, 95% CI 0.30–1.18; p = 0.095). However, Treatment-by-smoking interaction analyses did not detect statistically significant evidence. When participants were categorized as never smokers versus ever smokers (former or current smokers), ICIs were associated with significantly improved OS in both groups: never smokers (HR 0.75, 95% CI 0.66–0.85; p = 0.001) and ever smokers (HR 0.69, 95% CI 0.61–0.78; p = 0.003). ICIs were associated with improved OS in advanced ESCC in the overall population. However, in analyses by smoking status, OS benefit did not reach statistical significance among current smokers. Treatment-by-smoking interaction analyses did not detect statistically significant evidence. The analyses were limited by the small subgroup sizes, and further studies with larger smoking-stratified populations are needed.

BMC Cancer
Sana'a University (YE), Johannes Gutenberg University Mainz (DE), Korea University (KR), University of Tripoli (LY), University Medical Center of the Johannes Gutenberg University Mainz (DE)
Good health and well-being
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon